Cargando…
Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis
Rifampicin is an important agent for tuberculosis treatment; however, it is often discontinued because of adverse reactions. The treatment regimen then can be administered as that for rifampicin-resistant tuberculosis, which can be toxic. We retrospectively reviewed 114 patients with drug-susceptibl...
Autores principales: | Kim, Hyung-Jun, Lee, Ye Jin, Song, Myung Jin, Kwon, Byoung Soo, Kim, Yeon Wook, Lim, Sung Yoon, Lee, Yeon-Joo, Park, Jong Sun, Cho, Young-Jae, Lee, Choon-Taek, Lee, Jae Ho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338469/ https://www.ncbi.nlm.nih.gov/pubmed/37438379 http://dx.doi.org/10.1038/s41598-023-38394-1 |
Ejemplares similares
-
Usefulness of the BACES score in nontuberculous mycobacterial pulmonary disease for various clinical outcomes
por: Kim, Hyung-Jun, et al.
Publicado: (2023) -
Utility and safety of sole electromagnetic navigation bronchoscopy under moderate sedation for lung cancer diagnosis
por: Kim, Yeon Wook, et al.
Publicado: (2022) -
The significance of elevated tumor markers among patients with interstitial lung diseases
por: Kwon, Byoung Soo, et al.
Publicado: (2022) -
Impact of body weight change on clinical outcomes in patients with idiopathic pulmonary fibrosis receiving pirfenidone
por: Kim, Tae Hun, et al.
Publicado: (2022) -
The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis
por: Kwon, Byoung Soo, et al.
Publicado: (2020)